{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:34:06Z","timestamp":1785285246330,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012534","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000}}],"reference-count":108,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012534.pub2","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T16:06:49Z","timestamp":1531498009000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies"],"prefix":"10.1002","volume":"2018","author":[{"given":"Malgorzata M","family":"Bala","sequence":"first","affiliation":[{"name":"Jagiellonian University Medical College; Chair of Epidemiology and Preventive Medicine; Department of Hygiene and Dietetics; Systematic Reviews Unit - Polish Cochrane Branch; Kopernika 7 Krakow Poland 31-034"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Paszek","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Department of Interventional Cardiology; Pradnicka 80 Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Lesniak","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; 2nd Department of Internal Medicine; ul. Skawinska 8 Krakow Poland 31-066"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Wloch-Kopec","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Neurology Department; Botaniczna 3 Krakow Poland 31-503"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Jasinska","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Students' Research Group, Systematic Reviews Unit-Polish Cochrane Branch; Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Institute of Cardiology; Pradnicka 80 Krakow Poland 31-202"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"key":"10.1002\/14651858.CD012534.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00404-011-2055-y","article-title":"Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipid antibody syndrome","volume":"285","author":"Alalaf","year":"2012","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0002|cit2","first-page":"1285","article-title":"Primary prevention of thrombosis in antiphospholipid antibodies positive patients: a prospective, multicenter, randomised, open trial comparing low dose aspirin with low dose aspirin plus low intensity oral anticoagulation","volume":"60","author":"Cuadrado","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado","year":"2014","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijgo.2008.11.010","article-title":"Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome","volume":"104","author":"Dendrinos","year":"2009","journal-title":"International Journal of Gynaecology and Obstetrics"},{"issue":"7","key":"10.1002\/14651858.CD012534.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0006|cit6","first-page":"408","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3109\/01443615.2010.518651","article-title":"Efficacy and safety of two doses of low molecular weight heparin enoxaparin in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome","volume":"30","author":"Fouda","year":"2010","journal-title":"Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijgo.2010.09.010","article-title":"Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome","volume":"112","author":"Fouda","year":"2011","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijgo.2015.09.004","article-title":"Randomized controlled study of pre-conception thromboprophylaxis among patients with recurrent spontaneous abortion related to antiphospholipid syndrome","volume":"132","author":"Ismail","year":"2016","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0011|cit11","first-page":"25","article-title":"Prospective randomized trial of aspirin versus aspirin + heparin in pregnant women with a history of recurrent miscarriage in association with antiphospholipid antibodies","volume":"11 (Suppl 1)","author":"Rai","year":"1996","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0012|cit12","first-page":"5; abstract 20","article-title":"Prospective randomised trial of aspirin versus aspirin plus heparin in pregnant women with the antiphospholipid syndrome","volume":"93 (Suppl 1)","author":"Rai","year":"1996","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD012534.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0027-9684(15)30716-1","article-title":"Anticoagulation ineffective for recurrent miscarriage","volume":"102","year":"2010","journal-title":"Journal of the National Medical Association"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood.V126.23.2328.2328","article-title":"Rivaroxaban limits complement activation compared to warfarin in antiphospholipid syndrome patients with venous thromboembolism","volume":"126","author":"Arachchillage","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD012534.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/jth.13475","article-title":"Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism","volume":"14","author":"Arachchillage","year":"2016","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0016|cit16","first-page":"44","article-title":"Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome","volume":"147","author":"Cohen","year":"1996","journal-title":"Annales de Medecine Interne"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0017|cit17","first-page":"860","article-title":"RAPS: a prospective randomised controlled phase II\/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"11 (Suppl 2)","author":"Cohen","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD012534.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0961203315581207","article-title":"Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"24","author":"Cohen","year":"2015","journal-title":"Lupus"},{"issue":"9","key":"10.1002\/14651858.CD012534.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment","volume":"166","author":"Cowchock","year":"1992","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0002-9378(97)70409-5","article-title":"Do low-risk pregnant women with antiphospholipid antibodies need to be treated?","volume":"176","author":"Cowchock","year":"1997","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0022|cit22","unstructured":"Crowther MA Ginsberg JS Gent M Julian J Costantini L Kovacs M A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies Blood 2002 148a-Abstract 555"},{"issue":"12","key":"10.1002\/14651858.CD012534.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0024|cit24","first-page":"1028","article-title":"The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus","volume":"82","author":"Douketis","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD012534.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11 Part 1","key":"10.1002\/14651858.CD012534.pub2-BIB0026|cit26","first-page":"16a-Abstract OC","article-title":"A randomized clinical trial of two intensities of oral anticoagulant therapy in patients with the antiphospholipid syndrome: final results of the WAPS study","volume":"102","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0027|cit27","first-page":"CR132","article-title":"The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies","volume":"12","author":"Goel","year":"2006","journal-title":"Medical Science Monitor"},{"issue":"5","key":"10.1002\/14651858.CD012534.pub2-BIB0028|cit28","first-page":"33","article-title":"Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin","volume":"82","author":"Kondrat'eva","year":"2010","journal-title":"Terapevitcheskii Arkhiv"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh","year":"1996","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/annrheumdis-2015-eular.3942","article-title":"Beneficial effects of in vivo ubiquinol supplementation on athero-thrombosis prevention in antiphospholipid syndrome patients. Preliminary results of a clinical trial","volume":"74","author":"Lopez-Pedrera","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mefs.2013.12.004","article-title":"Enoxaparin and aspirin therapy for recurrent pregnancy loss due to anti-phospholipid syndrome (APS)","volume":"19","author":"Mohamed","year":"2014","journal-title":"Middle East Fertility Society Journal"},{"issue":"1","key":"10.1002\/14651858.CD012534.pub2-BIB0032|cit32","first-page":"64","article-title":"Implementation of an anticoagulation clinic at a teaching hospital: a descriptive study","volume":"18","author":"Moreira da Costa","year":"2015","journal-title":"Revista de Atencao Primaria a Saude"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0033|cit33","unstructured":"NCT02295475 Apixaban for the secondary prevention of thromboembolism among patients with the antiphospholipid syndrome (ASTRO-APS) clinicaltrials.gov\/ct2\/show\/NCT02295475"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0034|cit34","unstructured":"NCT02926170 Rivaroxaban for patients with antiphospholipid syndrome clinicaltrials.gov\/ct2\/show\/NCT02926170"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.fertnstert.2004.11.002","article-title":"Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin","volume":"83","author":"Noble","year":"2005","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11926-007-0030-1","article-title":"Clinical trials report","volume":"9","author":"O'Neil","year":"2007","journal-title":"Current Rheumatology Reports"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1067\/mob.2000.106754","article-title":"Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial","volume":"183","author":"Pattison","year":"2000","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0961203315611495","article-title":"Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial","volume":"25","author":"Pengo","year":"2016","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-009-0076-3","article-title":"Heparin and aspirin versus aspirin alone for prevention of recurrent pregnancy loss","volume":"12","author":"Roubey","year":"2010","journal-title":"Current Rheumatology Reports"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0040|cit40","first-page":"395","article-title":"Aspirin versus aspirin plus heparin in the treatment of women with habitual abortion and positive to anticardiolipin at low or moderate levels: a controlled trial","volume":"61","author":"Scarpellini","year":"2009","journal-title":"American Journal of Reproductive Immunology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1701-2163(16)30644-2","article-title":"Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin","volume":"26","author":"Stephenson","year":"2004","journal-title":"Journal of Obstetrics and Gynaecology Canada"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0042|cit42","first-page":"74","article-title":"A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with IVF-implantation failure and antiphospholipid or antinuclear antibodies","volume":"16 (Suppl 1)","author":"Stern","year":"2001","journal-title":"Human Reproduction (Oxford, England)"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0043|cit43","unstructured":"Villamil A Bandi JC Nunez F Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk liverlearning.aasld.org\/aasld\/2016\/thelivermeeting\/143869\/alejandra.villamil.antiphospholipid.antibodies.associated.vascular.events.are.html"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0045|cit45","first-page":"720","article-title":"Combined antiplatelet agents might help prevent arterial thromboses in antiphospholipid syndrome","volume":"7 (Suppl 2)","author":"Yamazaki","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0046|cit46","unstructured":"NCT03100123 Antiphospholipid syndrome low-molecular-weight heparin pregnancy loss evaluation: the pilot study (APPLE) clinicaltrials.gov\/ct2\/show\/NCT03100123"},{"issue":"6","key":"10.1002\/14651858.CD012534.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(99)80249-6","article-title":"Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations","volume":"99","author":"Abu-Shakra","year":"1995","journal-title":"American Journal of Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0048|cit48","first-page":"e44S-88S","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD012534.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003747.pub4","article-title":"Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)","author":"Alikhan","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD012534.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203315578765","article-title":"Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review","volume":"24","author":"Amengual","year":"2015","journal-title":"Lupus"},{"issue":"11","key":"10.1002\/14651858.CD012534.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care and Research"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmunity Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","article-title":"Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies","volume":"14","author":"Arnaud","year":"2015","journal-title":"Autoimmunity Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD012534.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD012534.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012169.pub2","article-title":"Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome","author":"Bala","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD012534.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11926-009-0072-7","article-title":"Antibodies to serine proteases in the antiphospholipid syndrome","volume":"12","author":"Chen","year":"2010","journal-title":"Current Rheumatology Reports"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0060|cit60","unstructured":"Veritas Health Innovation Covidence systematic review software, Available at www.covidence.org 2017"},{"issue":"7","key":"10.1002\/14651858.CD012534.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004734.pub4","article-title":"Aspirin and\/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia","author":"Jong","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-pharmtox-010814-124438","article-title":"New approaches to inhibiting platelets and coagulation","volume":"55","author":"Depta","year":"2015","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002859.pub2","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","author":"Empson","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012534.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"685-96","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmunity Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012534.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"e452-66","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0067|cit67","first-page":"e24S-43S","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2006-04-001206","article-title":"Current concepts on the pathogenesis of the antiphospholipid syndrome","volume":"109","author":"Giannakopoulos","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD012534.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"e3675","DOI":"10.1136\/bmj.e3675","article-title":"Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons","volume":"344","author":"G\u00f3mez-Outes","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48-9","author":"G\u00f3mez-Puerta","year":"2014","journal-title":"Journal of Autoimmunity"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0072|cit72","unstructured":"McMaster University (developed by Evidence Prime, Inc.) GRADEpro GDT: GRADEpro Guideline Development Tool 2015"},{"issue":"12","key":"10.1002\/14651858.CD012534.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/M15-2113","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force","volume":"164","author":"Guirguis-Blake","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0074|cit74","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD012534.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012198","article-title":"Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome","author":"Islam","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012534.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007557.pub3","article-title":"Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients","author":"Junqueira","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"issue":"45","key":"10.1002\/14651858.CD012534.pub2-BIB0080|cit80","first-page":"3155-79","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0081|cit81","unstructured":"Marchetti T Cohen M de Moerloose P Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications Clinical & Developmental Immunology 10.1155\/2013\/159124"},{"issue":"8","key":"10.1002\/14651858.CD012534.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD012534.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nature Reviews. Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"38","key":"10.1002\/14651858.CD012534.pub2-BIB0085|cit85","first-page":"2949-3003","article-title":"2013 guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council\u2019s General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"348726","DOI":"10.1155\/2014\/348726","article-title":"Review on effectiveness of primary prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety","volume":"2014","author":"Qushmaq","year":"2014","journal-title":"ISRN Rheumatology"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"293-8","DOI":"10.1016\/j.thromres.2006.10.025","article-title":"The effects of heparin and low molecular weight heparins on bone","volume":"122","author":"Rajgopal","year":"2008","journal-title":"Thrombosis Research"},{"issue":"10","key":"10.1002\/14651858.CD012534.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/0961203308095029","article-title":"Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome","volume":"17","author":"Rand","year":"2008","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012534.pub2-BIB0091|cit91","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"3","key":"10.1002\/14651858.CD012534.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"issue":"4","key":"10.1002\/14651858.CD012534.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD012534.pub2-BIB0095|cit95","first-page":"344","article-title":"Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European concerted action on the Immunogenetics of SLE","volume":"28","author":"Sebastiani","year":"1999","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012534.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/humrep\/17.4.1067","article-title":"Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure","volume":"17","author":"Sebire","year":"2002","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"167.e1","DOI":"10.1016\/j.ajog.2006.10.879","article-title":"Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies","volume":"196","author":"Shamonki","year":"2007","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"9","key":"10.1002\/14651858.CD012534.pub2-BIB0098|cit98","first-page":"652","article-title":"Histologic changes in placenta and chorion of women with antiphospholipid syndrome and inherited thrombophilia","volume":"82","author":"Skrzypczak","year":"2011","journal-title":"Ginekologia Polska"},{"issue":"18","key":"10.1002\/14651858.CD012534.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/eurheartj\/ehn310","article-title":"Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)","volume":"29","author":"Torbicki","year":"2008","journal-title":"European Heart Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD012534.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"e120S","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"Chest"},{"issue":"9","key":"10.1002\/14651858.CD012534.pub2-BIB0103|cit103","first-page":"688","article-title":"Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants","volume":"126","author":"Weitz","year":"2016","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012534.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD012534.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03999.x","article-title":"Anti-platelet therapy: ADP receptor antagonists","volume":"72","author":"Wijeyeratne","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD012534.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"37","key":"10.1002\/14651858.CD012534.pub2-BIB0107|cit107","first-page":"2541-619","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012534.pub2-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012534","article-title":"Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies","author":"Bala","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012534.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T13:30:22Z","timestamp":1685712622000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012534.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":108,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012534.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,13]]}}}